With expansion a prime focus for businesses worldwide, many are looking towards rapidly establishing new regions of growth, particularly in Asia, Pacifi c Rim countries.
To appear in our next issue, send your Business and Financial News stories to
heather@intlabmate.com The latest business developments from across Europe & Middle East
by Heather Hobbs
This section of International Labmate will especially look at the success of both Asian and European companies with established premises or business partnerships, highlighting the opportunities that exist while realising
potential for other companies to move into export markets.
Automated workfl ow advances purifi cation effi ciency
Tomas Blomquist, CEO, Biotage, said: “We’re excited to be partnering with Gyros Protein Technologies to bring a plate-based automated solution for parallel high- throughput peptide purifi cation to market, removing bottlenecks for peptide scientists, and providing a complete workfl ow solution from synthesis to evaporation. This partnership strengthens our position in the rapidly growing peptide market and supports our mission to provide high-quality, end-to-end separation and sample preparation solutions to scientists all over the world.”
Mark Vossenaar Tomas Blomquist
Swedish bioanalyticals provider Gyros Protein Technologies AB (part of Mesa Labs) and global life sciences company Biotage have jointly developed an automated plate-based peptide purifi cation workfl ow to provide a fast and environmentally sustainable solution for high-throughput peptide purifi cation.
Biotage PeptiPEC high-throughput kits leverage Gyros Protein Technologies’ proprietary PurePep® EasyClean (PEC™) catch and release technology, which combined with Biotage’s Extrahera automated platform is said to be able to purify up to 96 peptides in parallel 75% faster and with 98% lower solvent consumption in comparison to sequential HPLC.
Mark Vossenaar, Vice President, General Manager, Biopharmaceutical Development Division at Mesa Labs, commented: “By partnering with Biotage, we are taking a step further in our commitment to provide scientists with state-of-the-art peptide solutions across the entire value chain, from early research and screening to large-scale peptide production. The availability of our proprietary PEC purifi cation for automation in a plate-based format is equipping researchers with faster and more sustainable processes to advance their drug discovery.”
More information online:
ilmt.co/PL/bVAO 61797pr@reply-direct.com
Pre-validated hepatic cells alleviate need for QC testing
Organ-on-a-Chip (OOC) company CN Bio (Cambridge UK), a developer and manufacturer of single and multi-organ microphysiological systems has partnered with US-based LifeNet Health LifeSciences to supply validated primary human cells for use with CN Bio’s PhysioMimix® OOC range of MPS.
The partnership aims to provide ‘off-the-shelf’ access to well-characterised, MPS-validated hepatic cells to alleviate the need for researchers having to conduct resource-intensive validation studies and minimise the risk of failed experiments to increase workfl ow effi ciency.
Tomasz Kostrzewski Investment support for Software to increase Patient Safety
Clinicians can upload patient data based on observations and are given a real-time dashboard along with reporting tools that make sharing information easier.
James Burch said: “Acquired brain injury is not a new problem, but the statistics show it is a growing issue, which is causing a strain on both the public and private health sectors. With Melo, our focus is to provide a duty of care to staff who are responsible for looking after ABI patients who may, due to brain injury, express challenging behaviour.
Pictured (left to right: Jessica Jackson, Praetura Ventures; James Burch and James Chapman, Decently; Sim Singh- Landa, Praetura Ventures)
A new healthcare system which helps clinicians and hospital staff to track patients’ behaviour whilst they recover from brain trauma, has raised £500k to address potentially adverse episodes in healthcare settings.
James Burch and James Chapman, co-founders of Manchester-based company Decently, received backing for its Melo platform from the GMC Life Sciences Fund by Praetura, which is supported by the Greater Manchester Combined Authority, Cheshire & Warrington LEP and Bruntwood SciTech, with SFC Capital participating in the round.
The funding will be used to help launch Melo across the UK’s NHS and private rehabilitation care centres by scaling its team and grow awareness of this software technology, which is being piloted by three strategic northern NHS Trusts; the Northern Care Alliance NHS Foundation Trust, Leeds Teaching Hospitals NHS Trust and Liverpool University Hospitals NHS Foundation Trust.
Melo works by simplifying and streamlining the data capture process, using artifi cial intelligence to spot trends and behaviour escalation patterns in patients suffering acquired brain injuries (ABI) and injuries caused by non-birth related incidents, such as accidental trauma or a coma.
“By using Melo, we can help ease the manual and time- consuming burden of data capture and incident logging on an already stretched workforce, which we know from working closely with various NHS teams over the last 18 months can make a real signifi cant difference. We’re incredibly grateful for the support of the GMC Life Sciences Fund by Praetura and SFC Capital which helps us develop the business to the next level.”
Jessica Jackson, investment manager at Praetura Ventures, who joins Decently’s board as an Investment Director, said: “Decently’s launch of Melo is set to have a signifi cant impact on both clinician and patient safety and is yet another example of how tech innovation can drive improvements within the NHS, which continues to face cost and staffi ng pressures on a major scale. As well as providing investment from the GMC Life Sciences Fund by Praetura, we will be supporting Decently’s founders with more than money support to help scale its team and connect the company with key healthcare stakeholders.”
The investors also plan to connect the company with operational partner Mark Horncastle, previously a partner and the UK Head of Healthcare at PA Consulting, where he spent 12 years driving innovation and transformation which included the scaling of primary care services across Greater Manchester.
More information online:
ilmt.co/PL/4Z7m 61414pr@reply-direct.com
Tomasz Kostrzewski, PhD, Chief Scientifi c Offi cer at CN Bio, commented: “LifeNet Health and CN Bio share a commitment to helping researchers bring safer, more effective therapies to patients sooner, with no unnecessary animal testing.
“In our studies, LifeNet Health’s cells have consistently shown high success rates and we are confi dent this will lead to more reliable, reproducible results. Our partnership represents an important milestone for existing customers, alongside those looking to adopt OOC technology into their own labs.
“Validation of cells is a costly and laborious process, but one that is imperative for assay success. Harnessing our combined technical expertise and customer support, we can offer researchers a more complete solution to easily recreate our industry-leading liver models, removing the risk of failed experiments due to untested cells and the burden of in-house quality control testing – so that they can focus their efforts on new discoveries.”
Ed LeCluyse PhD, Chief Scientist, LifeNet Health LifeSciences, said: “This partnership represents a joint investment to set a new standard for cell quality across the industry, enabling customers across a broad range of market segments to realise the potential of OOC, without the need for costly in-house validation.”
“Our cells are fully characterised for quality and performance, to ensure they can perform within advanced platforms, to more effectively mimic in vivo biology.”
More information online:
ilmt.co/PL/kAeq 61801pr@reply-direct.com
Does your company sell or wish to sell laboratory products and services to the Europe and Middle East? Are you looking for local distributors and agents to represent you?
If so, why not advertise your products in our market-leading journal International Labmate.
Email:
info@intlabmate.com
Business
Opportunities
Europe & Middle East
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40
